Temporal Concept – Page 2

Pharma’s wins and losses in Trump’s sprawling executive order on drug prices

2 weeks ago talkbio0Tagged drug price, Industry, Insulin, IRA, losses, Mediation, Medicare, Prices, small molecule drugs

Medicare, Medicare, Industry, drug price, Mediation, small molecule drugs, losses, IRA, Insulin, Prices

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

2 weeks ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

Glycomine raises $115M to see if it can treat rare glycosylation disorder

2 weeks ago talkbio0Tagged Congenital disorder of glycosylation type 1A, GLM101, Glycomine, Infrequent

Infrequent, GLM101, Glycomine, Congenital disorder of glycosylation type 1A

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

2 weeks ago talkbio0Tagged Ayrmid, Capital, deadline, Failed, Family Turdidae (organism), gene therapy, Private Equity, proposal - intent, United States Food and Drug Administration

Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline

Trump pledges his support for a change to the IRA long sought by drugmakers

2 weeks ago talkbio0Tagged Biological Factors, Contraceptives, Oral, drug price, drugmakers, Industry, IRA, Mediation, Medicare, Prices

IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare

Navigating the Biotech Winter: Strategies for Survival and Growth Amid Ongoing Industry Downturn

2 weeks ago talkbio0Tagged Acquisitions, adaptation, Artificial Intelligence, biotech downturn, growth opportunities, innovation, Landscapes, layoff, Precision Medicine, regulatory, strategic, Survival, trends qualifier

biotech downturn, layoff trends, funding challenges, strategic adaptation, innovation, mergers & acquisitions, workforce planning, precision medicine, artificial intelligence, regulatory landscape, survival strategies, growth opportunities

Sanofi tempers its OX40 expectations in asthma after mid-stage miss

2 weeks ago talkbio0Tagged Amlitelimab, Asthma, exacerbations, Expectations, sanofi, Subgroup A Nepoviruses, TNFRSF4 gene

Asthma, Amlitelimab, TNFRSF4 gene, sanofi, exacerbations, Subgroup A Nepoviruses, Expectations

Sanofi backs $90M financing for I&I biologic developer

2 weeks ago talkbio0Tagged financing characteristics, I&I, sanofi, Series

sanofi, Series, financing characteristics, II

Illumina and Tempus look beyond cancer in new AI-driven genomics deal

2 weeks ago talkbio0Tagged Artificial Intelligence, Cardiology discipline, Genetic Profile, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Immunology, Malignant Neoplasms, Market, Neurology speciality, Partnership

Illumina, Genomics, Partnership, High-Throughput Nucleotide Sequencing, Malignant Neoplasms, Artificial Intelligence, Cardiology discipline, Neurology speciality, Immunology, Genetic Profile, Artificial Intelligence, Market

Bristol Myers says Camzyos fails Phase 3 study in genetic heart condition

2 weeks ago talkbio0Tagged Camzyos, Clinical Trials, Hypertrophic Cardiomyopathy, Hypertrophic cardiomyopathy without obstruction, Myers, Obstructed

Camzyos, Hypertrophic Cardiomyopathy, Myers, Hypertrophic cardiomyopathy without obstruction, Obstructed, Clinical Trials